Covid-19 Vaccine Protection among Children and Adolescents in Qatar

BACKGROUND: The BNT162b2 vaccine against coronavirus disease 2019 (Covid-19) has been authorized for use in children 5 to 11 years of age and adolescents 12 to 17 years of age but in different antigen doses. METHODS: We assessed the real-world effectiveness of the BNT162b2 vaccine against infection...

Descripción completa

Detalles Bibliográficos
Autores principales: Chemaitelly, Hiam, AlMukdad, Sawsan, Ayoub, Houssein H., Altarawneh, Heba N., Coyle, Peter, Tang, Patrick, Yassine, Hadi M., Al-Khatib, Hebah A., Smatti, Maria K., Hasan, Mohammad R., Al-Kanaani, Zaina, Al-Kuwari, Einas, Jeremijenko, Andrew, Kaleeckal, Anvar H., Latif, Ali N., Shaik, Riyazuddin M., Abdul-Rahim, Hanan F., Nasrallah, Gheyath K., Al-Kuwari, Mohamed G., Al-Romaihi, Hamad E., Butt, Adeel A., Al-Thani, Mohamed H., Al-Khal, Abdullatif, Bertollini, Roberto, Abu-Raddad, Laith J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Massachusetts Medical Society 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644642/
https://www.ncbi.nlm.nih.gov/pubmed/36322837
http://dx.doi.org/10.1056/NEJMoa2210058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644642/
https://www.ncbi.nlm.nih.gov/pubmed/36322837
http://dx.doi.org/10.1056/NEJMoa2210058

Ejemplares similares